1
Adult AD can present differently than in children and may require different treatment strategies, in part because patients tend to have thicker, more lichenified skin. 6 The most common areas of involvement in adult AD are the flexural surfaces of arms and legs, the nape of the neck, and the hands. AD can be severely problematic for adult patients, particularly when the exposed areas of the body are involved, such as the hands and face, and due to significant effects on overall quality of life. 6 The pathophysiology of AD is complex and includes genetic, immune, and environmental factors contributing to chronic inflammation. A simplified representation of the pathophysiology of AD is shown in Figure 1 . The current paradigm suggests that skin barrier dysfunction contributes to increased allergen penetration and microbial colonization, resulting in an immune response primarily driven by the type 2 inflammatory pathway. 7 The type 2 inflammatory pathway underlies the pathogenesis of many allergic and fibrotic disorders and is characterized by the Original Article production of cytokines such as interleukin (IL)-4, IL-5, and IL-13. 8 These cytokines may be produced by cells of the innate or adaptive immune system such as type 2 innate lymphoid cells (ILC2) and T helper 2 (Th2) cells, respectively. 9 Filaggrin gene (FLG) mutations resulting in barrier dysfunction are among the strongest risk factors for the development of AD. 7, 10 Filaggrin is known to be downregulated in adult patients with AD irrespective of FLG mutation status, highlighting the importance of the skin barrier in the development of the disease. 7 It is important to note that evidence of barrier dysfunction is observed even in nonlesional skin in patients with AD, which underscores the systemic nature of the disease.
11 Accordingly, early intervention from birth to maintain or repair skin barrier dysfunction through daily application of emollient may be protective against the development of AD in high-risk individuals. 12, 13 Barrier dysfunction may result in increased allergen penetration, microbial colonization, and metabolic disruption of the skin, the consequence of which is stimulation of the immune system primarily characterized by type 2 inflammation. [14] [15] [16] [17] The type 2 cytokines increased in AD include IL-4, IL-5, IL-13, IL-31, and thymic stromal lymphopoeitin (TSLP). 7, 18, 19 These cytokines are increased in lesional skin of patients with AD, suggesting a central role of the type 2 response in disease pathogenesis. 20 Type 2 inflammation leads to the downregulation of proteins important in maintaining normal epidermal barrier functions, including filaggrin. 7 Type 2 immune activation is also associated with increased mast cell activation, IgE production, and eosinophilia, which may predispose patients to allergic reactions. 21, 22 Type 2 inflammation may also contribute to alterations of the skin microbiome as well as pruritus. 7, [21] [22] [23] Oetjen et al 24 recently demonstrated that chronic pruritus is dependent on neuronal IL-4Rα signalling, suggesting a central role for IL-4 and IL-13 in the development of disease.
Pruritus, microbiome alterations, and environmental triggers collectively contribute to chronic inflammation and barrier dysfunction in AD. The skin in patients with AD has been shown to have increased innervation and decreased sensory nerve activation thresholds, thereby promoting pruritus. [25] [26] [27] Patients with AD also have decreased antimicrobial peptide (AMP) production resulting in increased microbial colonization and rates of skin infection, particularly with Staphylococcus aureus. 7, [28] [29] [30] Disease flares may be associated with both increased S aureus colonization and decreased microbial diversity in the skin microbiome. 29, 30 Finally, the skin of patients with AD is more prone to sensitization to environmental irritants and allergens. [31] [32] [33] Tobacco smoke and pollutants are associated with disease development. 32 Dry weather and hot showers that result in transepidermal water loss (TEWL), a hallmark of AD, are also known to exacerbate disease. [34] [35] [36] Other immune pathways have also been demonstrated to be important in AD pathogenesis. These include the Th22-and Th17-mediated inflammatory pathways, as well as the Th1 pathway in chronic disease. 7, [37] [38] [39] [40] However, their contribution to the development of AD is less well understood and seems to be less central than the type 2 pathway, as current evidence shows poor efficacy of drug candidates targeting the Th22, Th17, and Th1 pathways. 41, 42 The complex interplay between skin barrier dysfunction, microbial and allergen penetration, and immune dysregulation has several implications for the prevention and management of disease, as targeted therapies may affect more than one element of disease. The goal of any therapy is therefore to reduce skin inflammation and pruritus and to restore skin barrier function.
There are several options for the treatment of AD in adults, including topical therapies, phototherapy, and systemic therapies. Several groups have published detailed treatment guidelines or algorithms to assist health care providers in the diagnosis, assessment, and treatment of AD, with a main focus on moderate-to-severe disease. [43] [44] [45] [46] [47] [48] The selection criteria for candidates for systemic therapy in adults are quite similar among the guidelines and algorithms, which broadly defined candidates as patients with moderate-to-severe AD who have failed topical therapy and for whom phototherapy is unsuccessful or unsuitable. 45, 46, 48 With recent advances in our understanding of the complex pathophysiology of AD, the development of targeted therapeutics has become a reality and is leading the way to better clinical outcomes for patients with AD.
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